Vista Current Coverage

All Atossa Genetics, Inc. Articles

Atossa Genetics Expands Breast Health Program With Mens’ Initiative

Gynecomastia is male breast enlargement and accompanying pain. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed resulting is higher estrogen levels that usually triggers...

Vista Partners Publishes The February 2018 FREE Macroeconomic & Investment Monthly Newsletter

Vista Partners (“Vista”) has published February’s FREE Macroeconomic & Investment Monthly Newsletter, “Clear Skies Ahead?”. Vista’s monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Energy, Fintech, Healthcare, Manufacturing, Materials, Real Estate, SaaS, and Technology. Vista Partners centers its Coverage on the Dow 30...

“Steady Volatility” Vista Partners Weekly Market Update 2-24-18

Vista Partners has published “Steady Volatility” Vista Partners Weekly Market Update 2-24-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that...

Study Shows Aerobic & Resistance Exercise Serves Breast Cancer Survivors

Researchers from USC recently reported their study of breast cancer survivors showed that aerobic and resistance exercise produced significant improvements in cardiovascular disease, type 2 diabetes & possibly breast cancer recurrence. Atossa Genetics (NasdaqCM: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery...